NASDAQ: SABS
Sab Biotherapeutics Inc Stock Ownership - Who owns Sab Biotherapeutics?

Insider buying vs selling

Have Sab Biotherapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Andrew MoinDirector2025-09-291,740,000$1.75
$3.05MBuy
Sessa Capital Master LPDirector2025-09-291,740,000$1.75
$3.05MBuy

1 of 1

SABS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SABS insiders and whales buy or sell their stock.

SABS Shareholders

What type of owners hold Sab Biotherapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Vivo Capital LLC23.99%11,420,000$45.68MInstitution
Christine E. Hamilton23.61%11,237,694$44.95MInsider
Edward D. Hamilton21.06%10,023,848$40.10MInsider
Andrew Moin14.25%6,783,028$27.13MInsider
Ilan Katz12.81%6,097,150$24.39MInsider
Eddie Joe Sullivan10.99%5,232,304$20.93MInsider
Commodore Capital LP9.25%4,401,500$17.61MInstitution
Ra Capital Management LP9.25%4,401,500$17.61MInstitution
Samuel J. Reich8.01%3,814,524$15.26MInsider
Big Cypress Holdings LLC6.40%3,047,825$12.19MInsider

1 of 3

SABS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SABS35.08%64.92%Net BuyingNet Buying
SRZN24.33%75.67%Net BuyingNet Buying
MIST40.08%15.52%
RZLT44.64%55.36%Net BuyingNet Buying
STTK57.43%23.51%Net Buying

Sab Biotherapeutics Stock Ownership FAQ

Who owns Sab Biotherapeutics?

Sab Biotherapeutics (NASDAQ: SABS) is owned by 58.87% institutional shareholders, 108.92% Sab Biotherapeutics insiders, and 0.00% retail investors. Christine E. Hamilton is the largest individual Sab Biotherapeutics shareholder, owning 11.24M shares representing 23.61% of the company. Christine E. Hamilton's Sab Biotherapeutics shares are currently valued at $44.84M.

If you're new to stock investing, here's how to buy Sab Biotherapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.